ELSI assessment of data sharing will be conducted focusing on three levels:
(1) individual (patient) level, specifically on the use of next-generation sequencing (NGS), which presents challenges for securing truly informed consent and honouring patient preferences for the many different types of genetic information potentially yielded by NGS); (2) institutional level represented by various stakeholders (e.g. professional organisations in genetics and oncology, test laboratories, clinical trials networks) with vested interests in deciding which types of sequencing results to analyse and return to patients or research participants, and how to manage clinical implications; and (3) societal level, e.g. questions of resource allocation and priority setting. This task will be led by DYPEDE, Greece.